Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114799 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL17168337 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL16437865 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL10050599 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL10301493 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL14883433 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL16926031 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL8285384 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL20683157 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL102247 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250283129-A1 | PROCESS | SUN PHARMACEUTICAL INDUSTRIES AUSTRALIA PTY LIMITED (AU) | 2025-09-11 | — | — | US | claimed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | claimed |
| EP-4291018-A1 | PROCESS | Sun Pharmaceutical Industries (Australia) Pty Limited (AU) | 2023-12-20 | — | — | EP | claimed |
| EP-2125824-B2 | IMPROVED PREPARATION OF OXYMORPHONE FROM ORIPAVINE | MALLINCKRODT LLC (US) | 2023-11-15 | — | — | EP | claimed |
| EP-4112622-A1 | IMPROVED PROCESSES FOR MAKING OPIOIDS INCLUDING 14-HYDROXYCODEINONE AND 14-HYDROXYMORPHINONE | Macfarlan Smith Limited (GB) | 2023-01-04 | — | — | EP | claimed |
| US-20220079938-A1 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA, BETA-UNSATURATED KETONE COMPOUNDS | SpecGx LLC (US) | 2022-03-17 | — | — | US | claimed |
| US-20200338068-A1 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF a,ß-UNSATURATED KETONE COMPOUNDS | SpecGx LLC (US) | 2020-10-29 | — | — | US | claimed |
| EP-3250574-B1 | PROCESS OF PREPARING LOW ABUK OXYMORPHONE HYDROCHLORIDE | JOHNSON MATTHEY PLC (GB) | 2020-09-09 | — | — | EP | claimed |
| US-10649669-B2 | Processes for making opioids including 14-hydroxycodeinone and 14-hydroxymorphinone | JOHSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2020-05-12 | — | — | US | claimed |
| US-20190310778-A1 | Processes for Making Opioids Including 14-Hydroxycodeinone and 14-Hydroxymorphinone | MACFARLAN SMITH LIMITED (GB) | 2019-10-10 | — | — | US | claimed |
| US-20090005564-A1 | METHODS FOR N-DEMETHYLATION OF MORPHINE AND TROPANE ALKALOIDS | BROCK UNIVERSITY | 2009-01-01 | — | — | US | claimed |
| WO-2008118654-A1 | IMPROVED PREPARATION OF OXYMORPHONE FROM ORIPAVINE | MALLINCKRODT INC. (US) | 2008-10-02 | — | — | WO | claimed |
| WO-2008109156-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-20080146601-A1 | METHOD FOR MAKING ANALGESICS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2008-06-19 | — | — | US | claimed |
| WO-2008072018-A1 | IMPROVED METHOD FOR MAKING ANALGESICS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2008-06-19 | — | — | WO | claimed |
| US-20080125592-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2008-05-29 | — | — | US | claimed |
| WO-2008048957-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2008-04-24 | — | — | WO | claimed |
| WO-2008048711-A1 | PROCESS FOR PREPARING OXYMORPHONE | PENICK CORPORATION (US) | 2008-04-24 | — | — | WO | claimed |
| US-6365742-B1 | THEBAINE AND (N-METHYL)ANALOGUES CONTAINING A DIENOL ESTER OR ETHER FROM MORPHOLINE, CODEINONE OR ANALOGUES HAVING AN ALPHA-BETA UNSATURATED KETONE VIA A NOVEL ALKOXYLATED INTERMEDIATE | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2002-04-02 | — | — | US | claimed |
| EP-0889045-A1 | Process for the production of thebaine and analogues thereof, as well as intermediate products therefor | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1999-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005564-A1 | METHODS FOR N-DEMETHYLATION OF MORPHINE AND TROPANE ALKALOIDS | HNMT, NNMT, PNMT | OPRM1 4/4885OPRD1 14/4885OPRK1 12/4885 |
| US-20220079938-A1 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA, BETA-UNSATURATED KETONE COMPOUNDS | FASN, CYP1B1, CLN6 | OPRM1 69/4885OPRD1 50/4885OPRK1 98/4885 |
| US-20080125592-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRD1 2/4885OPRK1 1/4885 |
| US-20200338068-A1 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF a,ß-UNSATURATED KETONE COMPOUNDS | FASN, CYP1B1, CLN6 | OPRM1 76/4885OPRD1 62/4885OPRK1 123/4885 |
| US-10649669-B2 | Processes for making opioids including 14-hydroxycodeinone and 14-hydroxymorphinone | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRD1 2/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.